Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489819 | 0.89 | EGFR (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL14489815 | 0.87 | GPR119 (0.47) | GPR119ERBB2 | |
| SCHEMBL17729239 | 0.86 | GPR119 (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL31377576 | 0.85 | GPR119 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL30640003 | 0.85 | GPR119 (0.50) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL28983490 | 0.84 | PIK3CD (0.48) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL1527983 | 0.83 | EGFR (0.47) | GPR119ERBB2 | |
| SCHEMBL28983518 | 0.83 | PIK3CD (0.47) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| SCHEMBL633987 | 0.83 | PIK3CD (0.67) | PIK3CDPIK3CAPIK3CBPIK3CGGPR119 | |
| Hydrochloric Acid SCHEMBL4967454 | 0.82 | EGFR (0.46) | GPR119ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803326-B | EGFR inhibitor, preparation method thereof and application thereof in pharmacy | 上海和誉生物医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-115803326-A | EGFR inhibitor, preparation method and pharmaceutical application thereof | 上海和誉生物医药科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022105908-A1 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-05-27 | — | — | WO | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | PIK3CD 294/4885PIK3CA 284/4885PIK3CB 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.